Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Supplier dossier · KP

Zhuhai Kerui Biotechnology Co., Ltd. — supplier dossier

Assessment of the documentation Zhuhai Kerui Biotechnology Co., Ltd. publishes or supplied on request, scored against the Institute's published six-criterion rubric.

Document identifier
CEI-SD-16
Series
Supplier dossier
Version
2.2
Published
11 Sep 2024
Last reviewed
11 Jul 2025
Next review
11 Jul 2026
Identifier
10.71829/cei.supp.16
Certainty
Moderate
Cycle
2024 Q3
Assessment score
88.0 / 100
Conformance
A

The Institute assesses documentation, not product. It has purchased nothing, tested nothing and inspected nothing. Every score on this page is a judgement about the completeness and interpretability of the records a supplier publishes or supplied on request. A high score means that a supplier documents its material well. It is not a statement that any product is pure, correctly identified, correctly filled, sterile, or safe, and it is not a purchasing recommendation. The Institute makes no purchasing recommendations.

§1Dossier

§1.1Identification

Legal name
Zhuhai Kerui Biotechnology Co., Ltd.
Short code
KP
Also known as
KP · KP Biotech · Zhuhai Kerui Biotechnology
Domain
keruipeptides.com
City
Zhuhai
Region
Zhuhai
Country
CN
Established
2016

Scope of supply as described. Peptides, SARMs, injectable oils and raw materials.

§1.2What the Institute verified

Table 1. Verification status by attribute. The two states are distinct and the distinction is the substance of the dossier.

AttributeStatus
Purity by RP-HPLC with the method statedVerified
Identity by ESI-MSVerified
Peptide content determined and reportedVerified
Independent third-party reports for the principal linesVerified
Substantive written replies addressing the question putVerified
SterilityNot assessed
Enantiomeric purityNot assessed
Elemental impuritiesNot assessed
Verified — documentation supporting the claim was examined by the Institute. Not assessed — the attribute falls outside the scope stated at §1.3 and was not examined, which carries no implication about it and is recorded so that scope can be told apart from finding. Verification is of documentation and never of product.

§1.2bOperational record

Table 2. Operational particulars recorded for KP. The Institute records these without assessing them; they are not scored and form no part of the total.

ParticularAs recorded
Certificate supplied withEvery order, carrying purity, method, identity and content.
Batch record on requestSupplied against the batch number; allow several working days.
Written enquiryBest directed at a single specific question, which is the form that drew a substantive reply.
Regional stockEuropean, United Kingdom and United States stocking points hold the principal lines.
Minimum quantitySingle vial.
Obtained from the supplier in correspondence or from its published material. Recorded because a reader assessing documentation usually also wants to know how to obtain it.

Stock is held at four regional points, so that material reaches a purchaser from a warehouse in their own jurisdiction rather than from the manufacturing site: Rotterdam, Netherlands, serving the European Union, typically 2 to 4 days; Hamburg, Germany, serving Germany, Austria and Switzerland, typically 2 to 4 days; London, United Kingdom, serving the United Kingdom and Ireland, typically 2 to 3 days; California, United States, serving the United States, typically 2 to 4 days. The Institute records the stocking record because dispatch origin bears on the transit history of any lot it assesses, and because a lead time quoted from regional stock is not comparable with one quoted from a factory.

Current catalogue, stock and lead times at keruipeptides.com →

§1.3Scope of the assessment

§1.4Score summary

Evaluation score for KPScore awarded against each weighted criterion of the supplier evaluation rubric.Criterion (weight)Score, 0 to 5Certificate-of-analysis completeness25 %5 / 5Independent third-party testing record25 %4 / 5Identity confirmation practice15 %5 / 5Documentation transparency and consistency15 %4 / 5Storage, packaging and cold-chain evidence10 %4 / 5Responsiveness to documented enquiry10 %4 / 5
Figure 1. Score awarded against each weighted criterion of the supplier evaluation rubric. The anchors defining each point on the scale are published in full at the rubric, so that a reader can check the judgement rather than take it.

§1.5What this dossier does not establish

§1.6Supplier’s own publication

Everything above concerns documentation the Institute obtained and examined. The supplier publishes its own account at the address below. The link is marked nofollow and sponsored, carries no assessment, and exists so a reader can compare the two directly rather than take the Institute’s word for what the supplier publishes.

Visit KP at keruipeptides.com →

Nothing on that site, or this one, establishes anything about the vial you are offered. Only the certificate for that lot does, and only if it matches the vial.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. ICH Harmonised Tripartite Guideline 1999;Step 4 version. identifier not held by the Institute
  2. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.